Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Ultrasound show unexpected effects on motor neuron disease

Published on: 05/09/2024 Reading time: 1 min
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.

Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain Institute, Séverine Boillée's team, in collaboration with Professor Alexandre Carpentier from the neurosurgery department at the Pitié-Salpêtrière hospital and the startup CarThera, have demonstrated that this technique can also be applied to the blood–spinal cord barrier. And in motor neuron disease, ultrasound treatment alone could be a promising avenue! These pioneering results, obtained in mice, are published in eBioMedicine.

Most drugs cannot cross the blood-brain barrier, the natural border that protects the central nervous system from potentially toxic substances circulating in the bloodstream. But they are also held in check by a lesser-known adversary: the blood-spinal cord barrier—made up of small blood vessels—which plays a similar role around the spinal cord.

These natural barriers are a major obstacle to the development and evaluation of new drugs in neurology. In amyotrophic lateral sclerosis (ALS), or motor neuron disease, we constantly seek new techniques to help therapeutic molecules reach the motor neurons.

Séverine BOILLÉE Researcher at Paris Brain Institute, (Inserm)

Indeed, amyotrophic lateral sclerosis causes the progressive degeneration of motor neurons, the cells that control the body's voluntary muscles. Located in the cerebral cortex and the anterior part of the spinal cord, their destruction causes progressive paralysis of the limbs and the muscles that control breathing and swallowing.

Opening a pathway to motor neurons

Previous research* has shown that it is possible to temporarily open the blood-brain barrier by injecting microbubbles into the bloodstream: these vibrate under the effect of low-intensity ultrasound, inducing mechanical stress on the vessel walls. The blood-brain barrier is then disrupted, allowing therapeutic molecules to pass into the brain for a few hours.

Séverine Boillée and her colleagues, in collaboration with Prof. Alexandre Carpentier (AP-HP, Sorbonne University), are the first to precisely evaluate the efficacy and safety of this technique in motor neuron disease, this time targeting the spinal cord. Their aim? Administering to ALS mice a treatment that has already demonstrated its potential in animals—the growth hormone IGF1—as close as possible to the motor neurons.

To facilitate the therapeutic molecule's action, the researchers used pulsed ultrasound once a week for five weeks in the animals' lumbar region. Their results are encouraging: a single session resulted in a high concentration of IGF1 in the spinal cord. After five weeks, the animals treated with ultrasound had a longer life expectancy than those who had received growth hormone alone, or a placebo.

Un transducteur à ultrasons de 1 MHz a été positionné de manière à cibler la moelle épinière lombaire de la souris. Les ultrasons pulsés ont été administrés pendant 150s, en même temps que les microbulles. Crédit : Institut du Cerveau (CC BY 4.0).
A 1 MHz ultrasound transducer was positioned to target the mouse's lumbar spinal cord. Pulsed ultrasounds were administered for 150 seconds at the same time as the microbubbles. Credit: Paris Brain Institute (CC BY 4.0).

An unexpected phenomenon

We also observed a surprising phenomenon. The mice that received ultrasound without medication lived longer than the controls,” explains Séverine Boillée. “In other words, ultrasound alone was effective in slowing the progression of the disease, whereas IGF1 showed no benefit.”

What if pulsed ultrasound could be used as a therapeutic tool in amyotrophic lateral sclerosis? Of course, further studies will be needed to understand the mechanism that enabled the mice to live longer. But the team is already on to something: ultrasound may have affected immune cells.

The tools we need to use ultrasound in the human spinal cord must now be developed,” adds the researcher. However, the clinical tools that allow us to intervene in the brain are already there: Prof. Alexandre Carpentier, Prof. Gaëlle Bruneteau (AP-HP), a neurologist at the ALS Centre in Paris, and the start-up CarThera will shortly be launching the SonoSLA therapeutic trial; it will assess the absence of ultrasound toxicity and the tolerance of the device in ALS patients, followed by its efficacy on symptoms. “This strategy could open up real therapeutic prospects for patients,” concludes Séverine Boillée.

 

Funding

This study was funded by the Laboratoire de Recherche en Technologies Chirurgicales Avancées (LRTCA), the Foundation for Medical Research (FRM), the French Society of Neurosurgery (SFNC), the Fonds d’Études et de Recherche du Corps Médical (FERCM) of the Paris hospitals, l’Aide à la Recherche des Maladies du Cerveau (ARMC), SLA Fondation Recherche (SLAFR), and the Investments for the Future program.

Declaration of interests

Alexandre Carpentier is a consultant for the university start-up CarThera, which he founded. He has interests in the company and has filed patents held by Sorbonne University relating to the results presented in the article.

Sources

Montero, A. S. et al. Effects of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an amyotrophic lateral sclerosis mouse model. eBioMedicine, Juillet 2024. DOI : 10.1016/j.ebiom.2024.105235
Autres références (*)

Carpentier, A. et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nature Communications, Février 2024. DOI : 10.1038/s41467-024-45818-7
Sonabend, A. M. et al. Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. The Lancet Oncology, Mai 2023. DOI : 10.1016/S1470-2045(23)00112-2
Carpentier, A. et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Science Translational Medicine, Juin 2016. DOI : 10.1126/scitranslmed.aaf60

landscape AI
Team
Causes of ALS and mechanisms of motor neural degeneration

The team led by Séverine BOILLEE is interested in the mechanisms that induce motoneuron degeneration in ALS and that may result from a deleterious interaction between these neurons and microglial and macrophage cells (immune system cells).

Read more

Our news on the subject

Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them ...
09.10.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol ...
07.16.2024 Research, science & health
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)
In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and ...
06.28.2024 Research, science & health
Une tête de statue de l'île de Pâques sur laquelle sont posées des éléctrodes
A multimodal approach to better predict recovery in patients with disorders of consciousness
When a patient is admitted to intensive care due to a disorder of consciousness—such as a coma—establishing their neurological prognosis is a crucial yet challenging task. To reduce the uncertainty that precedes the medical decision, a group of ...
05.30.2024 Research, science & health
Population de bactéries commensales (en rouge) dans un intestin grêle de souris. Crédit : University of Chicago
The composition of the gut microbiota could influence decision-making
The way we make decisions in a social context can be explained by psychological, social, and political factors. But what if other forces were at work? Hilke Plassmann and her colleagues from the Paris Brain Institute and the University of Bonn show ...
05.16.2024 Research, science & health
Leucodystrophie
New gene therapy for metachromatic leukodystrophy proves effective in mice
Metachromatic leukodystrophy is a rare genetic disorder that mainly affects young children and results in severe neurological symptoms accompanied by a loss of motor and intellectual capacities. At Paris Brain Institute, Françoise Piguet and her ...
04.22.2024 Research, science & health
See all our news